Annual Cash & Cash Equivalents
$12.32 M
-$24.46 M-66.51%
31 December 2023
Summary:
Viracta Therapeutics annual cash & cash equivalents is currently $12.32 million, with the most recent change of -$24.46 million (-66.51%) on 31 December 2023. During the last 3 years, it has fallen by -$91.24 million (-88.11%). VIRX annual cash & cash equivalents is now -88.11% below its all-time high of $103.55 million, reached on 31 December 2021.VIRX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$13.13 M
-$854.00 K-6.11%
30 September 2024
Summary:
Viracta Therapeutics quarterly cash and cash equivalents is currently $13.13 million, with the most recent change of -$854.00 thousand (-6.11%) on 30 September 2024. Over the past year, it has increased by +$810.00 thousand (+6.58%). VIRX quarterly cash and cash equivalents is now -89.84% below its all-time high of $129.18 million, reached on 31 March 2021.VIRX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VIRX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | +6.6% |
| 3 y3 years | -88.1% | -87.3% |
| 5 y5 years | - | - |
VIRX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -88.1% | at low | -87.3% | +8.8% |
| 5 y | 5 years | -88.1% | at low | -89.8% | +8.8% |
| alltime | all time | -88.1% | at low | -89.8% | +8.8% |
Viracta Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $13.13 M(-6.1%) |
| June 2024 | - | $13.98 M(+15.9%) |
| Mar 2024 | - | $12.06 M(-2.1%) |
| Dec 2023 | $12.32 M(-66.5%) | $12.32 M(-4.2%) |
| Sept 2023 | - | $12.86 M(-10.1%) |
| June 2023 | - | $14.29 M(-21.0%) |
| Mar 2023 | - | $18.10 M(-50.8%) |
| Dec 2022 | $36.77 M | $36.77 M(+56.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2022 | - | $23.47 M(-71.2%) |
| June 2022 | - | $81.58 M(-11.5%) |
| Mar 2022 | - | $92.20 M(-11.0%) |
| Dec 2021 | $103.55 M(+119.9%) | $103.55 M(-6.7%) |
| Sept 2021 | - | $110.98 M(-9.6%) |
| June 2021 | - | $122.72 M(-5.0%) |
| Mar 2021 | - | $129.18 M(+174.3%) |
| Dec 2020 | $47.09 M | $47.09 M |
FAQ
- What is Viracta Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Viracta Therapeutics?
- What is Viracta Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Viracta Therapeutics?
- What is Viracta Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Viracta Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of VIRX is $12.32 M
What is the all time high annual cash & cash equivalents for Viracta Therapeutics?
Viracta Therapeutics all-time high annual cash & cash equivalents is $103.55 M
What is Viracta Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of VIRX is $13.13 M
What is the all time high quarterly cash and cash equivalents for Viracta Therapeutics?
Viracta Therapeutics all-time high quarterly cash and cash equivalents is $129.18 M
What is Viracta Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, VIRX quarterly cash and cash equivalents has changed by +$810.00 K (+6.58%)